|
|
|
| Performance evaluation of traditional Chinese medicine evaluation scale (ALS-SSIT scale) for therapeutic efficacy in amyotrophic lateral sclerosis |
| PAN Weidong1, WANG Qiudong2, ZHENG Xuanlu1, SIMA Dandan1, SCHRODER Joana1, WANG Mingzhe1 |
1. Department of Neurology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
2. Department of Neurology of Integration of Traditional Chinese and Western Medicine, Shanghai Pudong New District Hospital of Traditional Chinese Medicine, Shanghai 200120, China |
|
|
|
Abstract Objective: To evaluate the feasibility, reliability, validity and sensitivity of ALS-SSIT scale—a traditional Chinese medicine (TCM) evaluation scale for therapeutic efficacy in amyotrophic lateral sclerosis (ALS).
Methods: To summarize the experience in traditional Chinese medicine (TCM) in the treatment of ALS and consult experts’ suggestions, and then develop a scale (ALT-SSIT scale) suitable for evaluating the efficacy of TCM in the treatment of ALS. The performance of ALSSSIT scale was evaluated on the day of enrollment and after 6-month of follow-up in 160 patients with ALS who received traditional Chinese medicine treatment. The SF-36 and ALSFRS-R scales were used as references to evaluate the feasibility, reliability, validity and sensitivity of ALS-SSIT scale.
Results: The acceptance and completion rates of ALS-SSIT scale were both higher than 99%. The test-retest reliabilities of ALS-SSIT scale were 0.917 and 0.918 on the day of enrollment and after 6-month of follow-up, respectively. The content validity and sensitivity (total score, score of each field and score of each item) were higher. There was a linear correlation between ALS-SSIT scale and SF-36 and ALSFRS-R scales, which means that ALS-SSIT scale could better reflect the changes in disease condition.
Conclusion: The feasibility, reliability, validity and sensitivity of ALS-SSIT scale in evaluating the efficacy of TCM in the treatment of ALS are satisfactory, which is suitable for clinical application.
|
|
Received: 15 March 2021
Published: 17 March 2021
|
|
Corresponding Authors:
PAN Weidong E-MAIL ADDRESS: panwd@medmail.com.cn
|
|
|
|
|
|
|
